Health Care & Life Sciences » Biotechnology | Capricor Therapeutics Inc.

Capricor Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
4,166.70
3,776.00
3,998.60
2,666.30
671.40
Cost of Goods Sold (COGS) incl. D&A
26.90
-
-
-
-
-
Gross Income
26.90
-
-
-
-
-
SG&A Expense
7,379.20
10,762.80
18,048.60
20,870.50
15,414.60
16,870.80
EBIT
7,406.10
6,638.00
14,383.40
-
12,892.40
16,357.10
Unusual Expense
1,919.00
-
-
1,500.00
15,654.10
-
Non Operating Income/Expense
491.30
620.00
1,771.60
30.00
30.00
1,030
Interest Expense
58.10
200.50
248.60
344.70
398.80
-
Pretax Income
8,891.90
6,216.60
12,857.30
18,806.80
2,431.40
15,191.10
Consolidated Net Income
8,891.90
6,216.60
12,857.30
18,806.80
2,431.40
15,191.10
Net Income
8,891.90
6,216.60
12,857.30
18,806.80
2,431.40
15,191.10
Net Income After Extraordinaries
8,891.90
6,216.60
12,857.30
18,806.80
2,431.40
15,191.10
Net Income Available to Common
8,891.90
6,216.60
12,857.30
18,806.80
2,431.40
15,191.10
EPS (Basic)
0.85
0.53
0.81
1.01
0.09
5.17
Basic Shares Outstanding
10,501.40
11,697.00
15,902.10
18,551.00
23,193.30
2,941.10
EPS (Diluted)
0.85
0.53
0.81
1.01
0.09
5.17
Diluted Shares Outstanding
10,501.40
11,697.00
15,902.10
18,551.00
26,788.10
2,941.10
EBITDA
7,379.20
6,596.10
14,272.60
16,871.90
12,748.20
16,199.40
Non-Operating Interest Income
-
1.90
3.10
14.40
38.50
136

About Capricor Therapeutics

View Profile
Address
8840 Wilshire Boulevard
Beverly Hills California 90211
United States
Employees -
Website http://www.capricor.com
Updated 07/08/2019
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on November 20, 2013 and is headquartered in Beverly Hills, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.